We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Childhood Allergy and the Neonatal Environment (CANOE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04215783
Recruitment Status : Active, not recruiting
First Posted : January 2, 2020
Last Update Posted : February 15, 2023
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Duke University
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
The purpose of this research study is to study the relationship between childhood asthma, allergies, and early-life environmental factors that may cause childhood asthma and allergies. Previous birth cohort studies have found early-life environmental factors such as allergies, pollutants, viruses and bacteria have all contributed to the development of asthma and allergies. Investigators are doing this research because there continues to be a strong need to understand the root causes of asthma and allergies. The CANOE study is an observational cohort study, which means investigators are not asking participants or participant's child to change their medications and investigators will not be giving participants or participant's child a study drug.

Condition or disease
Asthma in Children Allergy

Detailed Description:
The CANOE study will provide an opportunity to collect novel longitudinal samples not available from the current CANOE birth cohorts, as well as enhanced and standardized environmental sampling in early life. One of the main goals of this study is to gather data and specimens, beginning in the prenatal periods, that will assess environmental exposures to toxins and microbes, and host characteristics including genetics, epigenetics, gene expression, the proteome and metabolome, microbial colonization and viral respiratory infections. The main study outcomes will be important interim conditions (e.g., recurrent wheeze, early multiple sensitization) that are highly associated with the development of asthma. Additional outcomes (perinatal outcomes, growth, neurocognitive development) will be collected as part of the collaborative Environmental Influences on Child Health Outcomes (ECHO)-wide Cohort Data Collection Protocol.

Layout table for study information
Study Type : Observational
Actual Enrollment : 499 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Childhood Allergy and the Neonatal Environment
Actual Study Start Date : March 4, 2020
Estimated Primary Completion Date : August 31, 2023
Estimated Study Completion Date : August 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy Asthma

Primary Outcome Measures :
  1. Number of children with recurrent wheeze [ Time Frame: 3 years ]
    Number of children with recurrent wheezing will be reported. Recurrent wheeze, defined as at least 2 episodes of wheeze with one occurring in the last 12 months of study participation for children between 2 and 3 years of age.

  2. Number of children with early aeroallergen sensitization [ Time Frame: 2 years ]
    Number of children with early aeroallergen sensitization will be reported. Early aeroallergen sensitization, defined as sensitization to at least one aeroallergens by age 2 years.

Secondary Outcome Measures :
  1. Number of children with Atopic dermatitis (AD) [ Time Frame: 3 years ]

    Number of children with AD will be reported. Atopic dermatitis, defined if at least 1 of the following is present:

    1. Physician diagnosis of eczema/AD (either study physician or other physician by parental report) at any time,
    2. Objective SCORAD (SCORing Atopic Dermatitis) ≥ 8 at 1 or more study assessments. The range of the objective SCORAD lies between 0 and 83. Based on the objective SCORAD, the severity of AD can be classified into mild (<15), moderate (between 15 and 40) and severe (greater than or equal to 40) AD.
    3. Parent report of an itchy rash outside of the diaper area lasting for at least 7 days and not diagnosed as another condition.

  2. Number of children with food allergies [ Time Frame: 3 years ]
    Number of children with the food allergy will be reported. Food allergy defined as typical signs and symptoms of immediate IgE (Immunoglobulin E) -mediated reaction (such as urticaria, angioedema, vomiting, wheezing, cough, hypotension) within 2 hours of food ingestion and with positive immunocap testing to that food.

Biospecimen Retention:   Samples With DNA
Cryopreserved samples of serum, plasma, urine, and nasal secretions or wash fluid, will be analyzed for proteins or metabolites that may serve as biomarkers for exposures or for study outcomes. A genetic sample (blood buffy coat or saliva) from the mother and child will be saved (if they agree) for use later to look at DNA, RNA or both.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study participants of CANOE will consist of four ethnically diverse cohorts from predominantly urban and suburban families at 4 sites. Previous studies have identified common themes in populations of children who differ by ethnicity and environmental exposures. These include inverse relationships between wheezing and/or atopy and exposure to specific microbes and allergens in early life. Obtaining prospective data from newly recruited participants during the prenatal period offers multiple opportunities to optimize sample collection for assessment of environmental exposures and enhance the scientific value of the CREW consortium. To enrich the cohort for the development of wheezing and allergic sensitization, we will enroll participants with a family history of asthma or allergies.

Inclusion Criteria:

  1. History of or concurrent asthma or allergic rhinitis (hay fever) in either biologic parent or sibling (at least one shared biological parent) by parental report. The presence of paternal or sibling allergy or asthma will be ascertained by maternal report.
  2. Maternal age greater than or equal to 18 years at the time of study enrollment.

Exclusion Criteria:

  1. Maternal HIV infection at time of delivery.
  2. Plans for the family to move out of the geographic area during the period of the study.
  3. Does not speak English.
  4. Current maternal use of progesterone during pregnancy to prevent preterm birth.

    • Progesterone use is only an exclusion if currently being taken at time of enrollment for preterm birth. Previous use to prevent preterm birth or use at any time for other indications is allowed.
  5. Pregnancy is a result of an embryo donor (egg and sperm donor pregnancies are permitted).
  6. Past or current medical problems or findings from physical examination or laboratory testing which, in the opinion of the investigator or designee, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04215783

Layout table for location information
United States, Michigan
Henry Ford Health Systems
Detroit, Michigan, United States, 48202
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Duke University
Layout table for investigator information
Principal Investigator: Anne Marie Singh, MD UW Madison
Principal Investigator: James Gern, MD UW Madison
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT04215783    
Other Study ID Numbers: 2019-1103
5UH3OD023282 ( U.S. NIH Grant/Contract )
A536770 ( Other Identifier: UW Madison )
SMPH/PEDIATRICS/AIR ( Other Identifier: UW Madison )
1U24AI152177-01 ( U.S. NIH Grant/Contract )
MSN236000 ( Other Grant/Funding Number: NIH ECHO program )
Protocol Version 4.0, 3/18/21 ( Other Identifier: UW Madison )
First Posted: January 2, 2020    Key Record Dates
Last Update Posted: February 15, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Wisconsin, Madison:
Allergy, Asthma, Children, Birth cohort
Additional relevant MeSH terms:
Layout table for MeSH terms
Immune System Diseases